Drug discovery

#Collaboration #Drug development #Drug discovery #Gene mutation #Research #Schizophrenia

This week in drug discovery (13-17 September) 

News round-up by DDW’s Megan Thomas for 13-17 September  The news in the drug discovery industry this week has demonstrated the potential that remains untapped for a number of industries at large as well as taking early steps towards future cures and treatments. DDW’s Megan Thomas has… Read More

#News #Trending News

#CRISPR #Drug development #Drug discovery #Gene editing #R&D

Benchling launch cloud solution at virtual event  

Benchling, the biotechnology cloud R&D platform used by organisations including Regeneron, Gilead and Pfizer, hosted a virtual event on September 14 at 8 am PT / 11 am ET called Drive Innovation from Discovery to Development, where the company announced its entry into the Early Development market, launching new solutions that… Read More

#News

#Collaboration #Drug discovery #Mass spectrometry / NMR #Parkinson's #Research #Schizophrenia #Therapeutics

This week in drug discovery (6-10 September) 

News round-up by DDW’s Megan Thomas for 6 – 10 September  DDW’s Megan Thomas selects five stories which showcase results, data, partnerships and research which offer a promising future for both drug development and eventual treatment of a number of diseases.   New potential therapy for… Read More

#News #Trending News

#AI #AI / data analytics / healthtech / informatics #Collaboration #Drug discovery #Molecular Biology

IBM Research and Arctoris accelerate closed loop drug discovery 

IBM Research and Arctoris are investigating the application of AI and automation to accelerate closed loop molecule discovery.   IBM Research has developed RXN for Chemistry, an online platform leveraging Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System),… Read More

#News #Trending News

#Drug development #Drug discovery #GlobalData #Novel therapeutics

PD market to reach $1.95 billion in 2030 driven by novel therapies

An upcoming influx of new therapies into the Pompe disease (PD) pipeline in the next decade is expected by GlobalData to provide a significant boost to the treatment market for this inherited, and often fatal, disorder that can greatly damage the heart and skeletal muscles. In fact, the market is expected… Read More

#News #Trends & Analysis

Seed funding
#Clinical trials #Covid-19 #Drug discovery #Funding #Research #Therapeutics

ILC Therapeutics completes £3.5 million funding round 

ILC Therapeutics has completed a £3.5 million pre-IPO funding round. Investors include Robert Kopple, Eos Angel Investment Syndicate, Scottish Enterprise and ILCT management.  Chairman Peter Bains said: “With this funding in place, ILCT is now well positioned to strengthen its novel technology platform and to advance its… Read More

#Business & Investment #News

#Clinical trial #Drug development #Drug discovery #Drug targets

Data shows promise for patients with asthma and comorbid nasal polyps 

New data from the Navigator Phase III trial showed that AstraZeneca and Amgen’s tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.1   Tezepelumab is a potential first-in-class treatment that acts by targeting thymic stromal lymphopoietin (TSLP), an… Read More

#News

#Collaboration #Covid-19 #Drug discovery #Research

This week in drug discovery (30 August – 3 September) 

News round-up by DDW’s Megan Thomas for 30 August – 3 September  DDW’s Megan Thomas has rounded up five stories in which studies, collaborations and trials pave the way towards treatments for a number of potentially fatal conditions.   1. NIH studies Covid-19 vaccine dose for… Read More

#News

#Drug discovery #Drug repurposing

Viagra can strongly suppress abnormal heart rhythms, finds study 

Scientists from the University of Manchester have found that the drug Viagra, used to treat sexual impotence, can strongly suppress abnormal heart rhythms known as arrythmias in sheep.  The British Heart Foundation funded study, published in Circulation Research, could have important implications on the management of the… Read More

#News

#Cardiovascular disease #Collaboration #Drug discovery

Novartis collaboration has potential to improve heart health in UK 

Novartis and NHS England are to pioneer a population health management approach to address elevated LDL-C in patients with Atherosclerotic Cardiovascular Disease (ASCVD) across England.  The collaboration received positive final recommendation from the National Institute for Health and Care Excellence (NICE) for use of inclisiran in primary care for the treatment of adult patients within… Read More

#Business & Investment #News

#Biopharmaceuticals #Clinical trials #Drug development #Drug discovery

Building a pipeline of clinically-differentiated cancer therapies 

As previously reported by DDW, Avacta Group has dosed the first patient in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin and the company’s first therapeutic based on its pre|CISION technology. Megan Thomas speaks Dr Alastair Smith, Chief Executive Officer of Avacta Group, about this development.  … Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Covid-19 #Drug development #Drug discovery #Podcast #Therapeutics

How Bamlanivimab reached clinic in eight months – podcast 

The latest DDW Sponsored Sitting Down With podcast features Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli Lilly and Co and Dan Bedinger, Application Science Team Lead, Carterra. Bamlanivimab was the first neutralising monoclonal antibody to receive emergency use authorisation from the FDA as a treatment for mild… Read More

#Covid-19 #News

#Cancer research #Clinical trials #Drug development #Drug discovery #Institute of Cancer Research

New cancer drug to enter first clinical trial targeting HSF1 pathway 

The Institute of Cancer Research (ICR), London has discovered an investigational drug called NXP800, which cancer patients are set to receive for the first time. It was discovered in a Phase I clinical trial sponsored by an oncology-focused biopharmaceutical company, Nuvectis Pharma.  The investigational oral drug inhibits the so-called… Read More

#Cancer Research #Trending News

#Biologics #Drug discovery #Drug therapy #Events #Immunotherapy

Two-day biologics drug discovery course open for registration 

Join Terrence Kenakin as he presents a two-day Applied course on September 21 and September 22 at 10AM CDT.   This two-day course will introduce the topic of biologics as a drug therapy in addition to recombinant replacement protein biologics, peptide signalling, immunotherapy, antibodies features, and nucleotide-based… Read More

#News

#Antibodies #Biotherapeutics #Collaboration #Drug discovery

Collaboration to support preclinical drug discovery research 

Fusion Antibodies has entered into a commercial collaboration with Eurofins to provide laboratories worldwide with high-quality, cost-effective and efficient services that work with one another to support biotherapeutic discovery.   Under the agreement, Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to… Read More

#Business & Investment #News

#AI #Biotechnology #Chemistry #Digital #Drug discovery #Life sciences

Digital Science launches research platform 

Digital Science has launched a new version of its Dimensions platform – Dimensions Life Sciences & Chemistry – focused on life sciences and chemistry research activities.   Dimensions L&C analyses more than 120 million scientific publications, millions of patents, grants and clinical trial documents. It applies semantic text analysis tools… Read More

#Business & Investment